Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

Dr. Coveler on Replacing 5-FU With NUC-3373 in mCRC

May 14th 2021

Andrew Coveler, MD, discusses the potential clinical implications of positive data with NUC-3373 in metastatic colorectal cancer.

Dr. Grothey on the Potential Role of ctDNA as a Marker for Rechallenging Treatment in CRC

May 14th 2021

Axel Grothey, MD, discusses the potential utility of circulating tumor DNA as a marker for rechallenging patients with treatment in colorectal cancer.

Best Practices Surrounding IO Treatment for mCRC

May 14th 2021

Kanwal Raghav, MD, MBBS, of The University of Texas MD Anderson Cancer Center, discusses when it is most appropriate to initiate immunotherapy for metastatic colorectal cancer, highlighting the roles of tumor mutation burden and microsatellite instability as biomarkers for treatment.

Frontline I-O Treatment for mCRC

May 14th 2021

Cathy Eng, MD, FACP, FASCO, describes data revealed by the KEYNOTE-177 trial and discusses best practices for using immunotherapy as first-line treatment of metastatic colorectal cancer.

Universal Genetic Testing Reveals Variants Linked With Increased Cancer Risk in CRC

May 13th 2021

One in 6 patients with colorectal cancer harbor genetic changes that substantially increase their risk for cancer, especially in those who are younger at the time of diagnosis.

3-Month Adjuvant CAPOX Represents Potential Option for Select High-Risk Stage II CRC

May 13th 2021

Three months of adjuvant capecitabine plus oxaliplatin represents a potential option for select patients with high-risk stage II colorectal cancer due to its convenience, reduced toxicity, and cost, although noninferiority to the 6-month standard duration was not demonstrated.

Dr. Messersmith on the Potential for Trastuzumab Deruxtecan in HER2+ CRC

May 12th 2021

Wells Messersmith, MD, discusses the potential for fam-trastuzumab deruxtecan-nxki as a treatment for patients with HER2-positive colorectal cancer.

Dr. Raghav on Adjusting Dosing With Regorafenib in CRC

May 11th 2021

Kanwal Raghav, MBBS, MD, discusses adjusting dosing with regorafenib in patients with colorectal cancer.

Dr. Raghav on Selecting Between TAS-102 and Regorafenib in CRC

May 10th 2021

Kanwal Raghav, MBBS, MD, discusses the process of selecting between treatment with trifluridine and tipiracil vs regorafenib in patients with colorectal cancer.

Biomarker Testing and Precision Medicine in mCRC

May 7th 2021

A panel of gastrointestinal oncologists discuss current options for molecular testing based on the understanding that predictive biomarkers play a role in the management of metastatic colon cancer.

Fruquintinib for Refractory mCRC

May 7th 2021

Expectations regarding the use of fruquintinib, an oral VEGF tyrosine kinase inhibitor, as third-line therapy for metastatic colorectal cancer.

Dr. Marshall on Early Data With Trastuzumab Deruxtecan in HER2+ CRC

May 6th 2021

John L. Marshall, MD, discusses early data reported with fam-trastuzumab deruxtecan-nxki in the treatment of patients with HER2-positive colorectal cancer from the phase 2 DESTINY-CRC01 trial.

Dr. Grothey on the Potential Role of ctDNA in Screening for CRC

May 5th 2021

Axel Grothey, MD, discusses the potential role of circulating tumor DNA testing in screening patients for early-stage colorectal cancer.

Primary Tumor Resection Plus Chemo is Not Recommended for Select Patients with Advanced CRC

May 5th 2021

Primary tumor resection followed by chemotherapy failed to demonstrate a survival benefit compared with chemotherapy alone in patients with stage IV colorectal cancer who have asymptomatic primary tumors and synchronous unresectable metastases, suggesting that PTR should no longer be considered a standard of care in this patient population.

Dr. Kazmi on Key Treatment Considerations for Young-Onset CRC

May 3rd 2021

Syed Kazmi, MD, an oncologist at The University of Texas Southwestern Medical Center, discusses key treatment considerations for young patients with onset colorectal cancer.

Trastuzumab Deruxtecan Under Investigation in HER2+ CRC in DESTINY-CRC02 Trial

May 3rd 2021

The first patient has received treatment with fam-trastuzumab deruxtecan-nxki in the phase 2 DESTINY-CRC02 trial, which is exploring the safety and efficacy of the antibody-drug conjugate in patients with HER2-overexpressing, BRAF wild-type, RAS-mutant or wild-type or mutant locally advanced, unresectable or metastatic colorectal cancer who have progressed following treatment with standard chemotherapy.

Dr. Osipov on the Role of Combination Immunotherapy Across Multiple Tumor Types

April 30th 2021

Arsen Osipov, MD, discusses the role of combination immunotherapy across multiple tumor types.

Best Strategies for Sequencing Regorafenib in mCRC

April 30th 2021

Considerations for how to sequence therapy with regorafenib for relapsed or refractory metastatic colorectal cancer based on the REVERCE II study.

TAS-102 for Refractory mCRC

April 30th 2021

Variables that impact patient selection for TAS-102 treatment as later-line therapy for metastatic colorectal cancer and considerations for using TAS-102 in combination with bevacizumab.

Regorafenib as Later-Line Treatment for mCRC

April 23rd 2021

The rationale for treating metastatic colon cancer with regorafenib in a later-line setting and the importance of applying the dose-escalation strategy demonstrated by the ReDOS trial into clinical practice.